{"analyses":[{"groupDescription":"The Wilcoxon Rank Sum Test was used to compare the Relative ΔSUVpeak (%) values between the standard and the treatment arms.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.43","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.5","value":"-38.2"},{"groupId":"OG001","spread":"41.8","value":"-40.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"To determine whether the relative change in SUVpeak (from the baseline to the during-treatment FDG-PET/CT) can predict the LRPF with a 2-year follow up.\n\nRelative ΔSUVpeak = (Mid-treatment SUVpeak - baseline SUVpeak)/baseline SUVpeak x 100 LRPF was determined from Randomization up to 2 years","dispersionType":"Standard Deviation","groups":[{"description":"60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel.\n\nBaseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19","id":"OG000","title":"Standard Radiation Therapy"},{"description":"A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19.\n\nBaseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19","id":"OG001","title":"Adaptive Radiation Therapy"}],"paramType":"MEAN","populationDescription":"All cases with both baseline and during-treatment FDG-PET/CT scans","reportingStatus":"POSTED","timeFrame":"Baseline to during-treatment (approximately between fractions 18-19) Randomization to 2 years","title":"Relative Change in SUVpeak From the Baseline to the During-treatment Fludeoxyglucose F 18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) to LRPF With a 2-year Follow up. (ECOG-ACRIN)","type":"PRIMARY","unitOfMeasure":"percent change"}